The Candida genus comprises opportunistic fungi that can become pathogenic when the
immune system of the host fails. Candida albicans is the most important and prevalent …

Cryptococcal meningitis is a leading cause of morbidity and mortality globally, especially in
people with advanced HIV disease. Cryptococcal meningitis is responsible for nearly 20% of …

To compensate for drug response variability, drug metabolism phenotypes are determined
based on the results of genetic testing, and if necessary, drug dosages are adjusted. In …

Chronic pulmonary aspergillosis (CPA) is estimated to affect 3 million people worldwide
making it an under recognised, but significant health problem across the globe, conferring …

Introduction Oral antifungals are used for the treatment of moderate-severe onychomycosis.
Terbinafine and itraconazole are approved for onychomycosis treatment in North America; …

Candida albicans is the most common clinical pathogenic fungus, which is highly
susceptible to immunodeficiency. Development of novel antifungal agents has become a …

Introduction There is an increasing number of reports of Trichophyton indotineae infections.
This species is usually poorly responsive to terbinafine. Areas covered A literature search …

Fungal infections, especially infections caused by Candida albicans, remain a challenging
problem in clinical settings. Despite the development of more-effective antifungal drugs, their …

The rate of fungal infections is increasing rapidly, and pathogenesis of their species is poorly
understood. Among fungi, Candida species are a major cause of morbidity and mortality …

Background Long‐term oral triazole antifungal therapy is the cornerstone of management for
patients with chronic pulmonary aspergillosis (CPA). Itraconazole is the first‐line choice of …